Plasma Epstein-Barr Virus DNA and Risk of Future Nasopharyngeal Cancer.

K C Allen Chan,W K Jacky Lam,Ann King, Vivien S Lin, Patrick P H Lee, Benny C Y Zee,Stephen L Chan, Irene O L Tse, Amy F C Tsang,Maggie Z J Li,Peiyong Jiang,Qi Yong H Ai,Darren M C Poon,K H Au,Edwin P Hui, Brigette B Y Ma,Andrew C Van Hasselt,Anthony T C Chan,John K S Woo, Y M Dennis Lo

NEJM evidence（2023）

引用 0|浏览6

暂无评分

摘要

EBV DNA Rescreening StudyPatients who had participated in a previous plasma Epstein-Barr virus (EBV) DNA screening study were rescreened. Of the 17,838 rescreened patients, 423 had persistently detectable plasma EBV DNA; 24 of these patients developed nasopharyngeal carcinoma. Sixty-seven percent of them received a diagnosis of early-stage disease and had increased progression-free survival compared with historical controls.

查看译文

关键词

epstein–barr virus dna,epstein–barr virus,cancer

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要